https://www.selleckchem.com/pr....oducts/ldc195943-imt
It is my pleasure to introduce myself to the readers of Biophysical Reviews as part of the 'Meet the Editors Series'.The treatment landscape of chronic lymphocytic leukemia (CLL) has undergone profound change in recent years. Targeted therapies have outnumbered chemotherapy-based treatment approaches demonstrating superior efficacy and tolerability profiles across nearly all CLL patient subgroups in the frontline and relapsed disease treatment setting. Individual selection of these novel agents is rather driven by patients' comor